BEACON-AA: Apixaban With or Without Clopidogrel in Stroke Patients With Atrial Fibrillation and Cerebral Atherosclerosis
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 586 participants.
Also called NCT07237308
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 586 participants
- Sponsor
- Registry
-
NCT07237308
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Recruiting
Technical summary
Registry record NCT07237308. Randomized; single masking; primary purpose prevention. Start 2026-07-14 (actual); primary completion 2029-07-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- BEACON-AA: Apixaban With or Without Clopidogrel in Stroke Patients With Atrial Fibrillation and Cerebral Atherosclerosis
- Condition
- Stroke
- Condition
- Ischemic
- Condition
- Atrial Fibrillation
- Condition
- Arteriosclerosis
- Condition
- Intracranial Arteriosclerosis
- Intervention (Drug)
- Apixaban
- Intervention (Drug)
- Clopidogrel
- Lead sponsor
- Yonsei University
Record details
- Record id
cardio:ct-nct07237308- Content hash
ec17214e9c9eac56f3daf73797146cbc7fbd189fe18bb16c0016e986cf08b4ed